Fehmı Tabak

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Mine Durusu Tanrıöver, Levent Doğanay, Murat Akova et al. · The Lancet · 2021 · 922 citations · Full text

Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b

Erik H.C.J. Buster, Hajo J. Flink, Yılmaz Çakaloğlu et al. · Gastroenterology · 2008 · 394 citations · Full text

Autoimmune Disease, Hbsag Loss, Peginterferon α-2B +4

Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B

Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma et al. · Gastroenterology · 2015 · 331 citations · Full text

Late HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis Delta

Benjamin Heidrich, Cihan Yurdaydın, Gökhan Kabaçam et al. · Hepatology · 2014 · 286 citations · Full text

Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels†

Vincent Rijckborst, Bettina E. Hansen, Yılmaz Çakaloğlu et al. · Hepatology · 2010 · 237 citations · Full text